Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
TCR2 Therapeutics Named One of the 15 Innovative Immuno-Oncology Biotechs to Watch in 2018 by Immuno-Oncology Frontiers | ||
By: PR Newswire Association LLC. - 15 Sep 2017 | Back to overview list |
|
CAMBRIDGE, Mass., Sept. 15, 2017 /PRNewswire/ -- TCR2 Therapeutics Inc. today announced that it has been named one of the "Top 15 Innovative Immuno-Oncology Biotechs to Watch in 2018" by Immuno-Oncology (IO) Frontiers. The list of honorees represents emerging players in the immunotherapy field with disruptive technologies that can transform the future treatment of cancer. Garry Menzel, Ph.D., Chief Executive Officer, will give an oral presentation highlighting the company's technology and lead programs at the IO Frontiers conference to be held on September 20-21 in Berlin, Germany. "We are honored to be recognized for the successful progress of our unique approach to battling solid tumors," said Dr. Menzel. "Our TRuC™-T cell platform represents a novel class of engineered T cell technology that engages the entire T cell receptor complex which we believe is critical for treating solid tumors. Using this approach, we have demonstrated superiority for our lead program TC-210 compared to CAR-T cells in preclinical studies and its potential to improve efficacy, safety and persistence in solid tumors. I look forward to sharing these data at this prestigious scientific forum." TCR2 Therapeutics Presentation at IO Frontiers
About TCR2 Therapeutics
View original content:http://www.prnewswire.com/news-releases/tcr2-therapeutics-named-one-of-the-15-innovative-immuno-oncology-biotechs-to-watch-in-2018-by-immuno-oncology-frontiers-300520210.html SOURCE TCR2 Therapeutics |
||
|
||
Copyright 2017 PR Newswire Association LLC. | Back to overview list |